Organon
OGN · NYSE · United States
Share price · OGN
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when OGN's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 27 Apr 2026+16.9%
- 24 Apr 2026+30.9%
Nothing announced by OGN that day or the session before.
- 10 Apr 2026+27.8%
Nothing announced by OGN that day or the session before.
- 9 Apr 2026+17.9%
Nothing announced by OGN that day or the session before.
- 25 Feb 2026-7.7%
Nothing announced by OGN that day or the session before.
- 20 Feb 2026+7.7%
- 12 Feb 2026-8.2%
- 26 Jan 2026-6.8%
Nothing announced by OGN that day or the session before.
Share of unusual movement by asset
For each asset, the share of OGN's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(12 total)
| Target & Modality | |||
|---|---|---|---|
| Approved | TNF-alphaMonoclonal antibody | Inflammatory Bowel DiseasePsoriatic ArthritisPsoriasisRheumatoid ArthritisHidradenitis SuppurativaNon-Infectious Uveitis Ulcerative Colitis, Crohn's Disease | |
| Approved | Dopamine D2 and serotonin 5-HT2A receptors (antagonist)Small molecule | SchizophreniaBipolar Disorder | |
BAT1806(Tofidence) | Approved | IL-6 receptorMonoclonal antibody | Rheumatoid ArthritisCOVID-19 |
Ezetimibe(Zetia) | Approved | Dietary Cholesterol Absorption Inhibitor · NPC1L1Small molecule | Atherosclerotic Cardiovascular DiseaseHomozygous Familial HypercholesterolemiaMixed Hyperlipidemia |
| Approved | HMG-CoA reductase / NPC1L1Small molecule | Atherosclerotic Cardiovascular DiseaseHomozygous Familial Hypercholesterolemia | |
| Approved | TNF-alphaMonoclonal antibody | Inflammatory Bowel DiseasePsoriatic ArthritisPsoriasisRheumatoid Arthritis Ulcerative Colitis, Crohn's Disease | |
mometasone furoate/formoterol fumarate(Dulera / Zenhale) | Approved | Glucocorticoid receptor; Beta-2 adrenergic receptorSmall molecule | Asthma |
| Approved | Cysteinyl leukotriene receptor 1 (CysLT1)Small molecule | Asthma | |
| Approved | 5-HT1B/1D receptorSmall molecule | Migraine | |
| Approved | Aryl hydrocarbon receptor · Aryl Hydrocarbon Receptor AgonistSmall molecule | Atopic DermatitisPsoriasis | |
| Approved | IL-12 p40Monoclonal antibody | Inflammatory Bowel DiseasePsoriatic ArthritisPsoriasis Ulcerative Colitis, Crohn's Disease | |
| Preclinical / Unstaged | HMG-CoA reductase / NPC1L1Small molecule | Atherosclerotic Cardiovascular Disease |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $1.6B | $83M | $1.5B | —$370M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $1.6B | $90M | $1.1B | —$107M operating cash flow | report ↗ |
| 2026-Q1 | $1.5B | $93M | $1.1B | —$225M operating cash flow | report ↗ |
| 2025-Q3 | $1.6B | $84M | $672M | —$264M operating cash flow | report ↗ |
| 2025-Q2 | $1.6B | $95M | $599M | —$220M operating cash flow | report ↗ |
| 2025-Q1 | $1.5B | $96M | $547M | —$75M operating cash flow | report ↗ |
| 2024-Q3 | $1.6B | $111M | $763M | —$141M operating cash flow | report ↗ |
| 2024-Q2 | $1.6B | $116M | $704M | —$332M operating cash flow | report ↗ |
| 2024-Q1 | $1.6B | $112M | $575M | —$76M operating cash flow | report ↗ |
| 2023-Q3 | $1.5B | $137M | $414M | —$261M operating cash flow | report ↗ |
| 2023-Q2 | $1.6B | $128M | $326M | —$27M operating cash flow | report ↗ |
| 2023-Q1 | $1.5B | $129M | $459M | —$114M operating cash flow | report ↗ |
| 2022-Q3 | $1.5B | $127M | $499M | —$317M operating cash flow | report ↗ |
| 2022-Q2 | $1.6B | $106M | $545M | —$151M operating cash flow | report ↗ |
| 2022-Q1 | $1.6B | $96M | $694M | —$123M operating cash flow | report ↗ |
| 2021-Q3 | $1.6B | $86M | $1.0B | — | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $6.2B | $366M | $574M | —$700M operating cash flow | report ↗ |
Organon reported full-year 2025 revenue of $6,216M, down 2.9% YoY, with R&D spend of $366M (down 22.0% YoY) and cash and equivalents of $574M. Net income was $187M for the year, and the company posted a fourth-quarter net loss of $205M, including a $301M non-cash goodwill impairment. Diluted EPS for the full year was $0.72.
For 2026, Organon expects revenue of approximately $6.2B and Adjusted EBITDA of approximately $1.9B, both roughly in line with 2025. The company highlighted FDA approvals of biosimilars Bildyos and Bilprevda in the third quarter of 2025, the acquisition of Tofidence in the second quarter of 2025, and the completed divestiture of the JADA system in January 2026. It also disclosed that its Audit Committee will review the timing of prior-year biosimilar purchases from a supplier, with no determination yet that anything inappropriate occurred.
Insider transactions
Open-market activity, trailing 12 months: 1 purchase ($353K), 2 sales ($553K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-13 | Morrissey Joseph T. Jr. · CEO | Option exercise | 43,744 | — | — | Form 4 |
| 2026-11-13 | Drinane Juliana Papa · Head of Mfg & Supply | Option exercise | 21,872 | — | — | Form 4 |
| 2026-11-13 | Morrissey Joseph T. Jr. · CEO | Tax withholding | 13,551 | $13.90 | $188K | Form 4 |
| 2026-11-13 | Drinane Juliana Papa · Head of Mfg & Supply | Tax withholding | 7,492 | $13.90 | $104K | Form 4 |
| 2026-11-13 | Morrissey Joseph T. Jr. · CEO | Option exercise (derivative) | 43,744 | — | — | Form 4 |
| 2026-11-13 | Drinane Juliana Papa · Head of Mfg & Supply | Option exercise (derivative) | 21,872 | — | — | Form 4 |
| 2026-11-07 | Arjona Ferreira Juan Camilo · Head of R&D & CMO | Option exercise | 6,447 | — | — | Form 4 |
| 2026-11-07 | Drinane Juliana Papa · Head of Mfg & Supply | Option exercise | 3,626 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 601 reporting institutions held 199.2M shares ($1.1B).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | BlackRock, Inc. | 31,717,028 | $190.0M |
| 2 | VANGUARD PORTFOLIO MANAGEMENT LLC | 21,846,036 | $130.9M |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 11,737,018 | $70.3M |
| 4 | STATE STREET CORP | 9,956,774 | $59.6M |
| 5 | MILLENNIUM MANAGEMENT LLC | 6,781,535 | $40.6M |
| 6 | KAHN BROTHERS GROUP INC | 5,536,993 | $33.2M |
| 7 | CANADA PENSION PLAN INVESTMENT BOARD | 5,011,100 | $30.0M |
| 8 | GEODE CAPITAL MANAGEMENT, LLC | 4,759,337 | $28.5M |
| 9 | PRIVATE MANAGEMENT GROUP INC | 4,374,108 | $26.2M |
| 10 | Think Investments LP | 4,000,000 | $24.0M |
| 11 | UBS Group AG | 3,471,579 | $20.8M |
| 12 | AQR CAPITAL MANAGEMENT LLC | 3,450,626 | $20.2M |
| 13 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 3,362,349 | $20.1M |
| 14 | MORGAN STANLEY | 3,292,684 | $19.7M |
| 15 | DIMENSIONAL FUND ADVISORS LP | 3,265,280 | $19.6M |